Stonepine Capital Management »

Humacyte shares owned by Stonepine Capital Management

Quarter-by-quarter ownership of Humacyte (HUMA) shares owned by Stonepine Capital Management from 13F filings

Historical chart of Stonepine Capital Management investment in Humacyte

Tip: Access up to 7 years of quarterly data

All positions including Humacyte held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Humacyte by Stonepine Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $181k 231k 0.78

More positions owned by Stonepine Capital Management

Evolus (EOLS)
Verastem Com New (VSTM)
Adma Biologics (ADMA)
Tenax Therapeutics Com New (TENX)
Nektar Therapeutics Com New (NKTR)
Ultragenyx Pharmaceutical (RARE)
Camp4 Therapeutics Corp Com 13469v Ab 4 Camtek Ltd Note 12/0 (CAMP)
Insmed Com Par $.01 Call Option (INSM)
Eloxx Pharmaceuticals Com New
Kazia Therapeutics Sponsored Ads (KZIA)
Medtronic SHS Call Option (MDT)
Indivior Pharmaceuticals (INDV)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Abbott Laboratories Call Option (ABT)
Satellos Bioscience (MSLE)

View all positions for Stonepine Capital Management

Top funds holding Humacyte

Vanguard Capital Management
Antipodes Partners
Alyeska Investment Group
Davidson Kempner Capital Management
BlackRock
Dr. Jeffrey R. Jay, M.D.
State Street Corporation
Susquehanna International
UBS Group
AQR Capital Management
Geode Capital Management
Millennium Management
Citadel Advisors
Charles Schwab Investment Management
Sixth Street Partners Management Company

View all funds holding Humacyte